Cathie Wood's ARK buys Intellia, 10x Genomics, sells Tesla stock

On Friday, May 30th, 2025, ARK ETFs significantly increased their positions in 10X Genomics (TXG) and Intellia Therapeutics (NTLA), purchasing shares valued at approximately $3.2 million and $1.7 million, respectively, signaling continued confidence in the genomic and gene-editing sectors. Conversely, ARK trimmed its holdings in Tesla (TSLA) by roughly $2.3 million and Adaptive Biotechnologies (ADPT) by over $1.5 million, continuing a trend of divestment and potentially indicating a strategic portfolio rebalancing. These moves reflect ARK's ongoing focus on innovative technologies while reallocating resources within its disruptive technology-focused portfolios.

Analysis

ARK ETFs executed significant trades on May 30th, 2025, notably increasing stakes in the biotechnology sector while reducing exposure to selected technology and electric vehicle companies. The firm acquired 342,179 shares of 10X Genomics Inc (TXG) for approximately $3.2 million across its ARKK and ARKG ETFs, reinforcing its confidence in the genomics company, as indicated by a +0.7 sentiment score for TXG. Similarly, ARK purchased 226,513 shares of Intellia Therapeutics Inc (NTLA) for about $1.7 million, also split between ARKK and ARKG, reflecting a growing conviction in the gene-editing field, supported by a +0.7 sentiment score for NTLA and a pattern of consistent buying. Conversely, ARK divested 6,511 shares of Tesla Inc (TSLA), valued at roughly $2.3 million, continuing a series of recent reductions and aligning with a -0.6 sentiment score, potentially signaling a strategic portfolio rebalancing. The firm also sold 164,741 shares of Adaptive Biotechnologies Corp (ADPT) for over $1.5 million via ARKG, extending a divestment trend and reflected in a -0.7 sentiment score. Additionally, 48,371 shares of 3D Systems Corp (DDD) were sold for approximately $77,393, consistent with recent reductions and a -0.6 sentiment score. These transactions, occurring within a general market sentiment assessed as mixed (0.0 sentiment score), highlight ARK's active management, emphasizing a long-term bullish stance on genomics and gene editing while reallocating capital away from other holdings within its disruptive technology-focused portfolios.

Key Decisions for Investors

• Investors should note ARK's reinforced bullish conviction in the genomics and gene-editing sectors, evidenced by substantial purchases in 10X Genomics (TXG) and Intellia Therapeutics (NTLA), potentially signaling attractive entry or accumulation points for those aligned with ARK's thematic focus.
• The continued selling of Tesla (TSLA), Adaptive Biotechnologies (ADPT), and 3D Systems (DDD) warrants careful consideration, suggesting investors might re-evaluate their exposure or monitor these names closely for further signs of strategic shifts by influential asset managers.
• Observe ARK's portfolio rebalancing as a potential indicator of evolving sentiment within disruptive technology; the capital rotation towards specific biotech names while trimming other tech holdings could inform sector allocation strategies and risk management.